Recent Quotes
View Full List
My Watchlist
01 Quantum Inc
DEFSEC Technologies Inc. - common stock, no R/S concurrent with offering
Defiance Leveraged Long + Income MSTR ETF
Exascale Labs Holdings Inc. - Class A Common Stock
INNIO N.V. - Ordinary Shares
Integra LifeSciences Holdings Corporation - Common Stock
Itm Power Plc
Iunits S&P/Tsx Capped Energy Index Fund
Lifeward Ltd. - Ordinary Shares
Maui Land & Pineapple Company, Inc. Common Stock
Medical Care Technologies Inc
Mercari Inc
Mitsui O.S.K. Lines ADR
Paladin Energy Ltd
Peer To Peer Network
Pirate Gold Corp
Principal Contrarian Value Index ETF
Scorpius Holdings, Inc. Common Stock
Silicon Laboratories, Inc. - Common Stock
Solstice Advanced Materials Inc. - Common Stock
Spectaire Holdings, Inc. - Warrants
Strikepoint Gold Inc
Sunshine Biopharma Inc. - Common stock
Traction Uranium Corp
Trinity Biotech plc - American Depositary Shares
VanEck Industrials TruSector ETF
Vecima Networks Inc
Vencanna Ventures Inc.
ViacomCBS Inc. - Class A Common Stock
Yorkville Acquisition Corp. - Class A Ordinary Share
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Zivo Bioscience, Inc. - Common Stock
(OP:
ZIVO
)
6.500
-0.014 (-0.21%)
Delayed Quote
Updated: 3:38 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Zivo Bioscience, Inc. - Common Stock
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
June 26, 2026
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
June 23, 2026
Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q2 2024
↗
August 16, 2024
Zivo Bioscience just reported results for the second quarter of 2024.
Via
InvestorPlace
ZIVO Bioscience Secures Commercial-Scale Manufacturing Agreement with Cyanotech Corporation for Zivolife™ Algal Biomass
April 06, 2026
From
Zivo Bioscience, Inc.
Via
Business Wire
ZIVO Bioscience Provides Special Letter to Shareholders
March 27, 2026
From
ZIVO Bioscience, Inc.
Via
Business Wire
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
September 10, 2025
From
ZIVO Bioscience, Inc.
Via
Business Wire
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO’s Immune-Enhancing Compounds in Poultry
June 20, 2025
From
ZIVO Bioscience, Inc.
Via
Business Wire
University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 06, 2025
From
ZIVO Bioscience, Inc.
Via
Business Wire
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
February 06, 2025
From
ZIVO Bioscience, Inc.
Via
Business Wire
ZIVO Bioscience to Present at The Microcap Conference 2025
January 22, 2025
From
Zivo Bioscience, Inc.
Via
Business Wire
ZIVO Bioscience Reports Progress with Coccidiosis Treatment Licensing Opportunities
December 23, 2024
From
Zivo Bioscience, Inc.
Via
Business Wire
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
December 20, 2024
From
Zivo Bioscience, Inc.
Via
Business Wire
ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens
August 23, 2024
From
ZIVO Bioscience, Inc.
Via
Business Wire
Major Global Animal Health Company Launches 42-Day Confirmatory Study with ZIVO Bioscience’s Coccidiosis Treatment in Broiler Chickens
July 08, 2024
From
ZIVO Bioscience, Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.